oxacillin + benzylpenicillin + ceftriaxone + doxycycline + clindamycin

This combination represents a regimen of five antibiotics—oxacillin, benzylpenicillin, ceftriaxone, doxycycline, and clindamycin—investigated by Danylo Halytsky Lviv National Medical University for the treatment of urogenital infections and bacterial vaginosis. The regimen utilizes a multi-targeted approach: the beta-lactam antibiotics (oxacillin, benzylpenicillin, and ceftriaxone) inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins; doxycycline, a tetracycline, inhibits protein synthesis by binding to the 30S ribosomal subunit; and clindamycin, a lincosamide, inhibits protein synthesis by binding to the 50S ribosomal subunit. In clinical research contexts, this antibiotic therapy is typically tailored based on sensitivity testing and followed by probiotic recovery treatments, such as Gynoflor, to restore healthy vaginal microflora.

Other names

oxacillin + benzylpenicillin + ceftriaxone + doxycycline + clindamycin-Danylo Halytsky Lviv National Medical University-bacterial vaginosis-urogenital infection